Through our rigorous science and the public quality standards we set, USP helps protect patient safety and improve the health of people around the world.
USP is led by experts who are driven to solve public health problems through science and innovation.
USP has been recognized as one of the best places to work in Biopharma.
GLP-1 solutions
USP is expanding the portfolio of Reference Standards, Analytical Reference Materials & Documentary Standards that help enable GLP-1 manufacturers to operate with high levels of confidence in the accuracy of their analytical results.
Reference Standards
USP Standards help accelerate the pharmaceutical drug development and manufacturing process and increase confidence in the accuracy of analytical results.
Microbiological quality control testing
Learn about USP's suite of ready-to-use products for microbiological quality control testing.
Impurities
Impurities pose risks to manufacturers, regulators and public health. USP can help.
Gene Therapy Analytical Guide
Explore the Gene Therapy Analytical Guide, an online interactive tool that places quality control solutions at your fingertips.
USP's commitment to sustainability
Featured Solutions
Learn about USP’s portfolio of solutions to help address quality assurance, enhance regulatory predictability, and help manufacturers distribute quality medicines, dietary supplements and foods.
USP Official Reference Standards
USP offers over 7,000 USP Reference Standards, highly characterized physical specimens of drug substances, excipients, food ingredients, impurities, degradation products, dietary supplements, compendial reagents, and performance calibrators.
Medicine Supply Map
USP’s Medicine Supply Map (MSM) is a graph-based predictive data model that generates insights into the upstream medicine supply chain. Using machine learning and advanced analytics, MSM identifies, characterizes, and quantifies factors linked to supply chain disruptions for drug ingredients and finished drug products.
Pharmaceutical Analytical Impurities
To protect patients, the FDA and other global regulatory agencies have issued public health alerts and guidance documents for manufacturers to assess and control the presence of nitrosamine impurities in medicines.